Does CDKN2A Loss Predict Palbociclib Benefit? | Zendy

Jennifer J. Gao | Zendy; R.P. Adams | Zendy; Sandra M. Swain | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Does CDKN2A Loss Predict Palbociclib Benefit?

Author(s) -

Jennifer J. Gao,

R.P. Adams,

Sandra M. Swain

Publication year - 2015

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.22.2700

Subject(s) - palbociclib , cdkn2a , medicine , letrozole , kinase , breast cancer , estrogen receptor , oncology , cancer research , cyclin dependent kinase , regulator , cancer , pharmacology , metastatic breast cancer , cell cycle , biology , tamoxifen , microbiology and biotechnology , biochemistry , gene

Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and Drug Administration in combination with letrozole for postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer. Patients with loss of CDKN2A (p16), an inherent negative regulator of cyclin-dependent kinases 4 and 6, were not separately studied because of the significant response of the patients selected based only on receptor status. Here, we report a patient with metastatic estrogen receptor- positive, her2-negative breast cancer with CDKN2A loss who experienced a clinical response to palbociclib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research